Borm FJ, Smit J, Oprea-Lager DE, Wondergem M, Haanen JBAG, Smit EF, et al. Response prediction and evaluation using PET in patients with solid tumors treated with immunotherapy. Cancers. 2021;13:3083.
Article CAS PubMed PubMed Central Google Scholar
Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Brit J Cancer. 2021;124:359–67.
Article CAS PubMed Google Scholar
Huang Y, Park Y, Wang-Zhu Y, Larange A, Arens R, Bernardo I, et al. Mucosal memory CD8+ T cells are selected in the periphery by an MHC class I molecule. Nat Immunol. 2011;12:1086–95.
Article CAS PubMed PubMed Central Google Scholar
Moebius U, Kober G, Griscelli AL, Hercend T, Meuer SC. Expression of different CD8 isoforms on distinct human lymphocyte subpopulations. Eur J Immunol. 1991;21:1793–800.
Article CAS PubMed Google Scholar
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.
Article CAS PubMed PubMed Central Google Scholar
Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O’Donoghue JA, et al. First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. J Nucl Med. 2020;61:512–9.
Article CAS PubMed PubMed Central Google Scholar
Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, et al. Preclinical development of ZED8 an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05968-6.
Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, Giesen D, Ungewickell A, Fine B, et al. Abstract LB037: 89ZED88082A PET imaging to visualize CD8+ T cells in patients with cancer treated with immune checkpoint inhibitor. 2021;81:LB037–LB037. https://doi.org/10.1158/1538-7445.AM2021-LB037.
Feo MSD, Pontico M, Frantellizzi V, Corica F, Cristofaro FD, Vincentis GD. 89Zr-PET imaging in humans: a systematic review. Clin Transl Imaging. 2022;10:23–36.
Rashidian M, Ploegh H. Nanobodies as noninvasive imaging tools. Immuno-oncology Technol. 2020;7:2–14.
Schoonooghe S, Laoui D, Ginderachter JAV, Devoogdt N, Lahoutte T, Baetselier PD, et al. Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology. 2012;217:1266–72.
Article CAS PubMed Google Scholar
Abdiche YN, Yeung AY, Ni I, Stone D, Miles A, Morishige W, et al. Antibodies targeting closely adjacent or minimally overlapping epitopes can displace one another. Plos one. 2017;12:e0169535.
Article PubMed PubMed Central Google Scholar
Otwinowski Z, Minor W. [20] Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–26.
Article CAS PubMed Google Scholar
McCoy AJ, Oeffner RD, Wrobel AG, Ojala JRM, Tryggvason K, Lohkamp B, et al. Ab initio solution of macromolecular crystal structures without direct methods. Proc Natl Acad Sci. 2017;114:3637–41.
Article CAS PubMed PubMed Central Google Scholar
Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr Sect D Biological Crystallogr. 2004;60:2126–32.
Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr Sect D Biological Crystallogr. 2010;66:213–21.
Genst ED, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc National Acad Sci. 2006;103:4586–91.
Gill H, Seipert R, Carroll VM, Gouasmat A, Yin J, Ogasawara A, et al. The production, quality control, and characterization of ZED8, a CD8-specific 89Zr-labeled immuno-PET clinical imaging agent. Aaps J. 2020;22:22.
Article CAS PubMed Google Scholar
Qi J, Leahy RM. Iterative reconstruction techniques in emission computed tomography. Phys Med Biol. 2006;51:R541–78.
Wang R, Natarajan K, Margulies DH. Structural basis of the CD8αβ/MHC class I interaction: focused recognition orients CD8β to a T cell proximal position. J Immunol. 2009;183:2554–64.
Article CAS PubMed Google Scholar
Sun J, Kavathas PB. Comparison of the roles of CD8 alpha alpha and CD8 alpha beta in interaction with MHC class I. J Immunol Baltim Md. 1950;1997(159):6077–82.
Bostrom J, Lee CV, Haber L, Fuh G. Therapeutic antibodies, methods and protocols. Methods Mol Biol. 2008;525:353–76.
Schneider TD, Stephens RM. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 1990;18:6097–100.
Article CAS PubMed PubMed Central Google Scholar
Barnett D, Storie I, Granger V, Whitby L, Reilly JT, Brough S, et al. Standardization of lymphocyte antibody binding capacity – a multi-centre study. Clin Lab Haematol. 2000;22:89–96.
Article CAS PubMed Google Scholar
Rashidian M, Ingram JR, Dougan M, Dongre A, Whang KA, LeGall C, et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017;214:2243–55.
Article CAS PubMed PubMed Central Google Scholar
Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97.
Article CAS PubMed Google Scholar
Ewert S, Cambillau C, Conrath K, Plückthun A. Biophysical properties of camelid VHH domains compared to those of human VH3 domains. Biochemistry-us. 2002;41:3628–36.
Mitchell LS, Colwell LJ. Comparative analysis of nanobody sequence and structure data. Proteins Struct Funct Bioinform. 2018;86:697–706.
Mitchell LS, Colwell LJ. Analysis of nanobody paratopes reveals greater diversity than classical antibodies. Protein Eng Des Sel. 2018;31:267–75.
Article CAS PubMed PubMed Central Google Scholar
Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541:321–30.
Article CAS PubMed Google Scholar
Echarti A, Hecht M, Büttner-Herold M, Haderlein M, Hartmann A, Fietkau R, et al. CD8+ and regulatory T cells differentiate tumor immune phenotypes and predict survival in locally advanced head and neck cancer. Cancers. 2019;11:1398.
Article CAS PubMed Central Google Scholar
Tolmachev V, Tran TA, Rosik D, Sjöberg A, Abrahmsén L, Orlova A. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med. 2012;53:953–60.
Article CAS PubMed Google Scholar
Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 affibody PET/CT. Theranostics. 2016;6:262–71.
Article PubMed PubMed Central Google Scholar
Sanchez-Crespo A. Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isotopes. 2013;76:55–62.
Rashidian M, Keliher EJ, Bilate AM, Duarte JN, Wojtkiewicz GR, Jacobsen JT, et al. Noninvasive imaging of immune responses. P Natl Acad Sci Usa. 2015;112:6146–51.
Barakat S, Berksoz M, Zahedimaram P, Piepoli S, Erman B. Nanobodies as molecular imaging probes. Free Radical Bio Med. 2022;182:260–75.
Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201–12.
Article CAS PubMed Google Scholar
Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res. 2017;77:2318–27.
Article CAS PubMed PubMed Central Google Scholar
Roth KS, Voltin C-A, van-Heek L, Wegen S, Schomaecker K, Fischer T, et al (2022) Dual-tracer PET/CT protocol with [ 18 F]-FDG and [ 68 Ga]Ga-FAPI-46 for cancer imaging - a proof of concept. J Nucl Med. jnumed.122.263835.
Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care. J Nucl Med. 2018;59:3–12.
留言 (0)